MarketPulse
R

$RLAY

4 articles found
2 positive
0 negative
2 neutral
The Motley FoolThe Motley Fool··Andy Gould

Swiss Biotech Fund Doubles Down on Relay With $6M Stake Bet

Swiss biotech fund Nextech Invest increases Relay Therapeutics stake by $6.1M, signaling institutional confidence in company's computational platform and clinical pipeline.
RVMDRVMDWRLAYXBIIBBinstitutional buyingbiotech investment
The Motley FoolThe Motley Fool··Jonathan Ponciano

Commodore Capital Expands Spyre Therapeutics Position as Stock Climbs 63% YoY

Commodore Capital increases Spyre Therapeutics stake to $78.24M as stock surges 63% YoY. Biotech firm has $757M cash and expects Phase 2 data in 2026.
ALKSSYRERLAYXENEbiotechbalance sheet strength
The Motley FoolThe Motley Fool··Jonathan Ponciano

Commodore Capital Cuts Nuvalent Position by $84M Despite Strong Stock Performance

Commodore Capital cuts $84M Nuvalent stake to 3.68% despite 29% stock gains. Biotech firm awaits September PDUFA decision for lead drug candidate.
RLAYNUVLFDA approvalclinical trials
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Relay Therapeutics to Report 2025 Results Ahead of Phase 3 Pipeline Milestones

Relay Therapeutics reports 2025 results February 26, highlighting progress on lead drug zovegalisib advancing through Phase 3 trials with FDA Breakthrough Therapy Designation.
RLAYPhase 3 clinical trialFDA Breakthrough Therapy Designation